• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Interius BioTherapeutics raises $76M Series A

May 18, 2021 By Sean Whooley

Interius BioTherapeuticsInterius BioTherapeutics announced today that it raised $76 million in an oversubscribed Series A financing round.

Philadelphia-based Interius develops treatments for hematologic malignancies. The company’s novel gene delivery platform generates chimeric antigen receptor (CAR) T cells directly in vivo to bypass the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required for standard CAR T cell treatments, according to a news release.

The company did not list an intended use of proceeds as a result of the offering but may use the funds to advance its existing platform and develop applications beyond immuno-oncology to address diseases that aren’t currently treatable through current gene therapy options.

Cormorant Asset Management and Fairmount Funds co-led the round, with new investors including Bain Capital Life Sciences, Pfizer Ventures, RA Capital Management, Longwood Fund, Logos Capital, Osage University Partners and Quan Capital. Tomas Kiselak of Fairmount Funds and Ben Lund of Bain Capital Life Sciences will join Interius’ board of directors.

All existing investors, including lead founding investor Tellus BioVentures, participated. Other existing investors include the University of Pennsylvania nad Penn Medicine, Agent Capital, the Mark Foundation for Cancer Research, Knollwood and BrightEdge, the American Cancer Society’s impact investment fund.

“We were gratified by the exceptional interest during our raise and are delighted by the composition of the syndicate – a testament to the potential of the technology and the solid scientific foundation from Dr. Gill’s lab and the Center for Cellular Immunotherapies at Penn,” Interius CEO Dr. Phil Johnson said in the release. “I look forward to working with this amazing team as we advance our gene delivery platform that will enable highly specific, durable re-engineering of cells right where they live in the human body.”

Filed Under: Business/Financial News, Featured, Funding Roundup, Immunotherapy, Oncology Tagged With: Interius BioTherapeutics

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS